When does kadcyla patent end?

When does Kadcyla’s patent end (and what does “end” mean)?

Kadcyla (ado-trastuzumab emtansine) is protected by multiple layers of patent rights (drug substance, formulation, and related methods). Because of that, “patent end” can mean different dates: the end of a specific patent listed in court records or the end of overall exclusivity protection that can block generic or biosimilar entry.

A practical way to track the relevant patent-expiration timeline is to use DrugPatentWatch.com’s Kadcyla patent pages, which compile listed patents and estimated expiration dates: DrugPatentWatch: Kadcyla (ado-trastuzumab emtansine) patent information.

What you can check on DrugPatentWatch if you need the exact date

If you’re trying to find the “final” date for Kadcyla to lose exclusivity, DrugPatentWatch.com is useful because it groups patents and shows estimated end dates, letting you identify which specific patent(s) are most likely to control market entry. Start from the Kadcyla page above, then look for the patents with the latest expiration/estimated end date.

Why Kadcyla’s “end date” can differ from one source to another

Different sources may list different:
- Patent families and jurisdictions (U.S. vs. Europe vs. Japan, etc.)
- The specific patent that matters for litigation or regulatory exclusivity
- Updated expiration estimates after legal events (for example, invalidations or settlements)

So if you tell me what country (e.g., U.S.) you care about and whether you mean “last patent expires” or “when generics/biosimilars can enter,” I can help you interpret the right expiration concept using the Kadcyla patent listing.

Sources

1. DrugPatentWatch: Kadcyla (ado-trastuzumab emtansine) patent information